| Business Summary | | Avigen
Inc.
is
a
leader
in
the
development
of
gene
therapy
products
for
the
treatment
of
inherited
diseases.
The
Company
is
developing
a
broad-based
proprietary
gene
delivery
technology
based
on
adeno-associated
virus
vector
technology,
known
as
AAV
vectors,
to
deliver
DNA
into
the
cells
of
patients
that
are
suffering
from
genetic
diseases.
AAV
vectors
are
a
relatively
new
system
for
gene
therapy.
The
Company
believes
that
AAV
vectors
can
be
used
to
deliver
genes
for
the
treatment
of
hemophilia,
Gaucher
disease,
Parkinson's
disease
and
beta-thalassemia. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Avigen,
Inc.
develops
gene
therapy
products
derived
from
adeno-associated
virus
for
the
treatment
of
inherited
and
acquired
diseases.
The
products
are
designed
for
in
vivo
administration
to
achieve
the
production
of
therapeutic
proteins
within
the
body.
For
the
fiscal
year
ended
6/30/01,
revenues
rose
100%
to
$116
thousand.
Net
loss
increased
6%
to
$16
million.
Revenues
reflect
increased
grant
revenues.
Higher
loss
reflects
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Philip Whitcome, Ph.D., 52 Chairman | $180K | -- | John Monahan, Ph.D., 53 Pres,
CEO | 402K | $416K | Thomas Paulson, 54 VP,
Fin., CFO and Sec. | 262K | 1.7M | Janice Castillo VP,
Regulatory Affairs | -- | -- | Elliott Grossbard, M.D. VP,
Clinical Affairs | -- | -- | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|